Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin.

作者: Egon Persson , Tina Foscolo , Martin Hansen

DOI: 10.1002/RTH2.12167

关键词:

摘要: Background Factor VIII (FVIII) procoagulant activity is commonly assessed by measuring the activated partial thromboplastin time (APTT) to clot formation using one of many available but differently composed reagents. The majority APTT reagents also accurately recover extended half-life molecule N-glycoPEGylated FVIII (N8-GP; turoctocog alfa pegol), while a few silica-based give low recovery. Objective To identify cause N8-GP underestimation in presence certain Methods Development FVIIIa-dependent tenase and appearance FVIIIa from its non-PEGylated counterpart (N8) were compared clotting assays, factor Xa (FXa) assay mimic thereof, thrombin activation courses. Results A strong correlation was demonstrated between FXa assays based on similar recoveries equal responses an altered duration contact phase, validating latter as useful mimic. Contact phase influenced, could even eliminate, underestimation. Thrombin-catalyzed conversion considerably slower than that N8 despite extents adsorption silica particles APTT-SP, suggesting different modes and/or orientations adsorption. Conclusions Some activators reduce thrombin's ability cleave more native FVIII. Decelerated reflected delayed plasma, turn leading prolonged time. This forms basis for measured one-stage against standard.

参考文章(14)
E. K. Waters, I. Hilden, B. B. Sørensen, M. Ezban, P. K. Holm, Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive. Journal of Thrombosis and Haemostasis. ,vol. 13, pp. 2041- 2052 ,(2015) , 10.1111/JTH.13134
L. THIM, B. VANDAHL, J. KARLSSON, N. K. KLAUSEN, J. PEDERSEN, T. N. KROGH, M. KJALKE, J. M. PETERSEN, L. B. JOHNSEN, G. BOLT, P. L. NØRBY, T. D. STEENSTRUP, Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. ,vol. 16, pp. 349- 359 ,(2010) , 10.1111/J.1365-2516.2009.02135.X
N. S. Key, S. Kitchen, K. Signer-Romero, Current laboratory practices in the diagnosis and management of haemophilia: a global assessment Haemophilia. ,vol. 21, pp. 550- 557 ,(2015) , 10.1111/HAE.12639
Henning R. Stennicke, Marianne Kjalke, Ditte M. Karpf, Kristoffer W. Balling, Peter B. Johansen, Torben Elm, Kristine Øvlisen, Flemming Möller, Heidi L. Holmberg, Charlotte N. Gudme, Egon Persson, Ida Hilden, Hermann Pelzer, Henrik Rahbek-Nielsen, Christina Jespersgaard, Are Bogsnes, Anette A. Pedersen, Anne K. Kristensen, Bernd Peschke, Wendy Kappers, Frederik Rode, Lars Thim, Mikael Tranholm, Mirella Ezban, Eva H. N. Olsen, Søren E. Bjørn, A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models Blood. ,vol. 121, pp. 2108- 2116 ,(2013) , 10.1182/BLOOD-2012-01-407494
J. Dodt, A. R. Hubbard, S. J. Wicks, E. Gray, B. Neugebauer, E. Charton, G. Silvester, Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia. ,vol. 21, pp. 543- 549 ,(2015) , 10.1111/HAE.12634
J-M. Gu, P. Ramsey, V. Evans, L. Tang, H. Apeler, L. Leong, J. E. Murphy, V. Laux, T. Myles, Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia. ,vol. 20, pp. 593- 600 ,(2014) , 10.1111/HAE.12374
S. Kitchen, G. Kershaw, S. Tiefenbacher, Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues Haemophilia. ,vol. 22, pp. 72- 77 ,(2016) , 10.1111/HAE.13012
Stefan Tiefenbacher, Robert Gosselin, Steve Kitchen, Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies Seminars in Thrombosis and Hemostasis. ,vol. 43, pp. 331- 337 ,(2017) , 10.1055/S-0037-1598058